Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Trial details
- Registry ID
- NCT06973629
- Drugs studied
- Debamestrocel - MSC-NTF (NurOwn)
TrialRedline tracks 4 clinical trials sponsored by Brainstorm-Cell Therapeutics: 2 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)NCT06973629 | Debamestrocel - MSC-NTF (NurOwn) | Not yet recruiting | 2028-11-01Estimated |
| Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsNCT03280056 | Bone Marrow aspiration, NurOwn® (MSC-NTF cells) | Completed | 2020-09-29Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSNCT03799718 | NurOwn (MSC-NTF cells) | Completed | 2021-03-11Actual |
| Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSNCT02017912 | Nurown MSC-NTF cells | Completed | 2016-03Actual |
Names as written in the registry records.